SUPERNUS PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M |
| Cost of revenue | $74.6M | $77.9M | $83.8M | $87.2M | — |
| Cash from operations | $47.3M | $172.0M | $111.1M | $116.8M | $127.1M |
| Capital expenditure | $1.3M | $725,000 | $551,000 | $412,000 | — |
| Free cash flow | $46.0M | $171.2M | $110.5M | $116.4M | — |
| Impairments | $0 | $0 | $0 | — | — |
| Total assets | $1.5B | $1.4B | $1.3B | $1.7B | $1.7B |
| Total liabilities | $390.9M | $332.3M | $356.2M | $816.3M | $873.3M |
Shares outstanding 58.0M · Free float 80.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.